Clinical outcome in solid organ transplant recipients with COVID-19: A single-center experience

Travi, Giovanna; Rossotti, Roberto; Merli, Marco; Sacco, Alice; Lauterio, Andrea; Colombo, Valeriana; Carlis, Luciano De; Frigerio, Maria; Minetti, Enrico; Belli, Luca; Puoti, Massimo

doi:10.1111/ajt.16069

Cited by 31 publications

(40 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Days of ICU stay, median (IQR) 11 (5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21) 11 (7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19) .42…”

Section: Primary Outcomesunclassified

“…19 Small case series from the United States have also reported similar mortality rates in SOT patients with COVID-19 that have been observed in the general population. [20][21][22][23] In addition, there is no data available for outcomes of COVID-19 infected SOT patients admitted in intensive care units. Our paper is aimed to address this knowledge gap.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States

Molnar

Bhalla

Azhar

et al. 2020

American Journal of Transplantation

110

View full text Add to dashboard Cite

National data on patient characteristics, treatment, and outcomes of critically ill coronavirus disease 2019 (COVID‐19) solid organ transplant (SOT) patients are limited. We analyzed data from a multicenter cohort study of adults with laboratory‐confirmed COVID‐19 admitted to intensive care units (ICUs) at 68 hospitals across the United States from March 4 to May 8, 2020. From 4153 patients, we created a propensity score matched cohort of 386 patients, including 98 SOT patients and 288 non‐SOT patients. We used a binomial generalized linear model (log‐binomial model) to examine the association of SOT status with death and other clinical outcomes. Among the 386 patients, the median age was 60 years, 72% were male, and 41% were black. Death within 28 days of ICU admission was similar in SOT and non‐SOT patients (40% and 43%, respectively; relative risk [RR] 0.92; 95% confidence interval [CI]: 0.70‐1.22). Other outcomes and requirement for organ support including receipt of mechanical ventilation, development of acute respiratory distress syndrome, and receipt of vasopressors were also similar between groups. There was a trend toward higher risk of acute kidney injury requiring renal replacement therapy in SOT vs. non‐SOT patients (37% vs. 27%; RR [95% CI]: 1.34 [0.97‐1.85]). Death and organ support requirement were similar between SOT and non‐SOT critically ill patients with COVID‐19.

show abstract

“…Days of ICU stay, median (IQR) 11 (5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21) 11 (7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19) .42…”

Section: Primary Outcomesunclassified

Section: Introductionmentioning

confidence: 99%

Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States

Molnar

Bhalla

Azhar

et al. 2020

American Journal of Transplantation

110

View full text Add to dashboard Cite

show abstract

“…11 These early case reports have now been supported by 3 cohort studies from transplanted patients in Europe. [12][13][14] In a study from Spain, 29 kidney transplant recipients with COVID-19 were evaluated. One group of patients (n = 6) were reduced in calcineurin inhibitor dose and the second group (n = 23) either continued their usual cyclosporine dose or were switched from tacrolimus to cyclosporine.…”

Section: Introductionmentioning

confidence: 99%

Cyclosporine and COVID-19: Risk or favorable?

Poulsen

Brunn

Hornum

et al. 2020

American Journal of Transplantation

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID‐19) pandemic is declared a global health emergency. COVID‐19 is triggered by a novel coronavirus: severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Baseline characteristics of admitted patients with COVID‐19 show that adiposity, diabetes, and hypertension are risk factors for developing severe disease, but so far immunosuppressed patients who are listed as high‐risk patients have not been more susceptible to severe COVID‐19 than the rest of the population. Multiple clinical trials are currently being conducted, which may identify more drugs that can lower mortality, morbidity, and burden on the society. Several independent studies have convincingly shown that cyclosporine inhibit replication of several different coronaviruses in vitro. The cyclosporine‐analog alisporivir has recently been shown to inhibit SARS‐CoV‐2 in vitro. These findings are intriguing, although there is no clinical evidence for a protective effect to reduce the likelihood of severe COVID‐19 or to treat the immune storm or acute respiratory distress syndrome (ARDS) that often causes severe morbidity. Here, we review the putative link between COVID‐19 and cyclosporine, while we await more robust clinical data.

show abstract

“…In a larger case series of 90 organ transplant recipients, including 43 patients after renal transplantation with COVID-19 from an outbreak in New York, high rates of severe disease (39%) and mortality (24%) were observed [ 3 ]. However, single- and multi- center studies reported similar outcomes from organ transplant patients after COVID-19, mainly without increased mortality and morbidity compared to the general population [ 4 , 5 , 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

Low Seroprevalence of SARS-CoV-2 Antibodies during Systematic Antibody Screening and Serum Responses in Patients after COVID-19 in a German Transplant Center

Choi

Bachmann

Naik

et al. 2020

JCM

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 denotes a global health issue. Data regarding COVID-19 incidence in kidney transplant recipients (KTR) are sparse. From 19 March to 19 May 2020, we performed a systematic screening for COVID-19 in KTR. Tests included serum analysis for SARS-CoV-2 antibodies using S protein-based immunofluorescence, anti-SARS-CoV-2 S1 immunoglobulin G (IgG) and immunoglobulin A (IgA) enzyme-linked immunosorbent assays (ELISA), and/or quantitative reverse transcription polymerase chain reaction (qRT-PCR) from nasal-throat swabs. Outpatient serum samples from KTR with PCR confirmed COVID-19, and swab samples from recipients (+donors) undergoing kidney transplantation were analyzed. Out of 223 samples from outpatients, 13 patients were positive with solely anti-SARS-CoV-2-IgA and 3 with both anti-IgA and anti-IgG. In total, 53 patients were symptomatic in the past, but positive results could be found in both symptomatic and asymptomatic patients. After an in depth analysis using immunofluorescence and neutralization tests in 2 KTR, recent COVID-19 infection remained highly suspicious. Apart from outpatient visits, only 5 out of 2044 KTR were symptomatic and tested positive via PCR, of which 4 recovered and one died. All patients showed seroconversion during the course of the disease. This study demonstrated a low seroprevalence in a German KTR cohort, and seroconversion of IgA and IgG after COVID-19 could be demonstrated. Effective containment strategies enabled us to continue our transplant program.

show abstract

Clinical outcome in solid organ transplant recipients with COVID-19: A single-center experience

Cited by 31 publications

References 5 publications

Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States

Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States

Cyclosporine and COVID-19: Risk or favorable?

Low Seroprevalence of SARS-CoV-2 Antibodies during Systematic Antibody Screening and Serum Responses in Patients after COVID-19 in a German Transplant Center

Contact Info

Product

Resources

About